Impact of 18 FDG PET/CT on the Management of Patients With Staphylococcus Aureus Bloodstream Infection

NACompletedINTERVENTIONAL
Enrollment

291

Participants

Timeline

Start Date

January 29, 2018

Primary Completion Date

March 20, 2025

Study Completion Date

March 20, 2025

Conditions
Staphylococcus Aureus
Interventions
PROCEDURE

PET/CT Positron emission tomography (PET) using small radiotracers, a special camera and a computer to evaluate organ and tissue functions

"Open-label randomized controlled superiority trial in patients with SAB without infective endocarditis at the time of inclusion comparing whole-body PET/CT in arm A and routine care with performance of imaging studies according to anamnesis and clinical symptoms in arm B. To demonstrate that PET/CT is associated with a 20% higher frequency of detection of DFI during SAB, the inclusion of 145 patients in each arm is required.~Randomization will be stratified on centre and SAB setting of acquisition (healthcare vs community)."

OTHER

Patients' routine care with performance of explorations based on anamnesis and clinical symptoms

Patients' routine care with performance of explorations based on anamnesis and clinical symptoms

Trial Locations (1)

34295

Chu Gui de Chauliac, Montpellier

All Listed Sponsors
lead

University Hospital, Montpellier

OTHER

NCT03419221 - Impact of 18 FDG PET/CT on the Management of Patients With Staphylococcus Aureus Bloodstream Infection | Biotech Hunter | Biotech Hunter